Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

11:02 AM ET Form 4
Insider Selling Procter & Gamble Co PG

Procter & Gamble CFO Andre Schulten Sells $5.18M of Stock

Andre Schulten, CFO, sold 30,677 shares of Procter & Gamble Co at $169.00 a share, worth $5.18M in total on Nov 5, 2026. Shares held after the trade: 65,618 (-31.9%).

Value
$5.18M
Shares
30,677
Price
$169.00
Role
CFO
Holding change
-31.9%
Trade date
Nov 5, 2026
11:01 AM ET Form 4
Insider Selling Procter & Gamble Co PG

Procter & Gamble CEO - Grooming de Azevedo Juliana Monteiro Santos Sells $908K of Stock

de Azevedo Juliana Monteiro Santos, CEO - Grooming, sold 5,370 shares of Procter & Gamble Co at $169.00 a share, worth $908K in total on Nov 5, 2026. Shares held after the trade: 21,361 (-20.1%).

Value
$908K
Shares
5,370
Price
$169.00
Role
CEO - Grooming
Holding change
-20.1%
Trade date
Nov 5, 2026
10:52 AM ET Form 4
Insider Buying Ttm Technologies Inc TTMI

Ttm Technologies Director Philip G. Franklin Buys $310K of Stock

Philip G. Franklin, Director, bought 5,000 shares of Ttm Technologies Inc at $61.92 a share, worth $310K in total on Nov 5, 2026. Shares held after the trade: 161,725 (+3.2%).

Value
$310K
Shares
5,000
Price
$61.92
Role
Director
Holding change
+3.2%
Trade date
Nov 5, 2026
10:50 AM ET 8-K/A
Capital Raise Muzinich Corporate Lending Income Fund, Inc.

Muzinich Corporate Lending Income Fund Capital Raise of $3M

Muzinich Corporate Lending Income Fund, Inc. sold 2,909.57 shares of common stock in an unregistered private placement for aggregate proceeds of $3.0 million. The shares were priced at $1,031.08 per share and issued to accredited investors under Section 4(a)(2) and Regulation D exemptions.

Value
$3M
10:49 AM ET 10-Q
Financial Results Claritev Corp CTEV ▶ Call

Claritev Q3 2026 Results: Net Loss of $61.8M, Loss Narrows

Claritev Corporation reported a net loss of $61.8 million for the third quarter of 2026, an improvement from the $69.8 million loss in the prior year period, driven by a 9% increase in revenues to $268.3 million. Despite higher operating income, the company remains heavily burdened by $100.9 million in quarterly interest expense and carries a total shareholders' deficit of $339.9 million.

Key figure
Net loss $61.8M
10:46 AM ET 8-K
Loan & Debt WF Card Funding LLC

WF Card Funding Debt Financing Update

WF Card Issuance Trust, a vehicle of Wells Fargo Bank, announced it expects to issue Class A(2026-2) Notes on November 12, 2026. The company entered into an underwriting agreement and terms agreement on November 5, 2026, for the issuance of these asset-backed securities.

10:45 AM ET 8-K
Capacity Expansion Oppenheimer Holdings Inc OPY

Oppenheimer Holdings Capacity Expansion

Oppenheimer Holdings' subsidiary Viner Finance entered into a 15.5-year lease for approximately 221,339 square feet at 32 Old Slip in Lower Manhattan to serve as its new principal headquarters. The relocation involves a $66 million investment and will house executive management, research, trading, and investment banking operations starting in early 2028. The agreement includes fixed annual rent starting at $13.3 million and provides for significant capital expenditures for technology and infrastructure upgrades.

Counterparty
RXR 32 Old Slip Owner LLC
Term
15.5 years
10:14 AM ET 8-K
Investor Presentation Cincinnati Financial Corp CINF

Cincinnati Financial Investor Presentation

Cincinnati Financial Corporation has posted a formal investor presentation deck to its website for use in meetings beginning November 10, 2026. The presentation outlines the company's long-term strategy, including a target Value Creation Ratio (VCR) of 10% to 13% over the next five-year period. Key performance drivers highlighted include premium growth above industry averages and a target combined ratio between 92% and 98%.

10:12 AM ET
Earnings Call Ceco Environmental Corp CECO ▶ Call

Ceco Environmental Earnings Call: Key Takeaways

CECO delivered record Q3 results with revenue doubling to $404 million, driven by the Thermon acquisition and 30% organic growth, while providing aggressive 2027 guidance.

Call
Nov 9, 2026, 8:30 AM ET
10:09 AM ET 10-Q
Financial Results CNH Industrial N.V. CNH ▶ Call

CNH Industrial Q3 2026 Results: Net Income $30M, Down 62.5% YoY

For the quarter ended September 30, 2026, CNH Industrial reported total revenues of $4.35 billion, a slight decrease from $4.40 billion in the prior year. Net income attributable to the company fell to $30 million ($0.02 per share) compared to $80 million ($0.06 per share) in 2025, primarily impacted by a significantly higher income tax expense during the period.

Key figure
Net income $30M · -62.5% YoY
10:08 AM ET Form 4
Insider Selling Provident Financial Holdings Inc PROV

Provident Financial Holdings Insider Craig G. Blunden Sells $104K of Stock

Craig G. Blunden sold 5,700 shares of Provident Financial Holdings Inc at $18.20 a share, worth $104K in total on Nov 5, 2026. Shares held after the trade: 202,284 (-2.7%).

Value
$104K
Shares
5,700
Price
$18.20
Holding change
-2.7%
Trade date
Nov 5, 2026
10:06 AM ET 10-Q
Financial Results Regions Financial Corp RF

Regions Financial Q3 2026 Results: Net Income $631M, Up 10.9% YoY

Regions Financial Corporation reported 848,847,340 shares of common stock outstanding as of November 6, 2026. The filing outlines significant risk factors including market interest rate fluctuations, credit losses, and potential weaknesses in residential and commercial real estate markets.

Key figure
Net income $631M · +10.9% YoY
10:03 AM ET 8-K
Capital Raise Monroe Capital Enhanced Corporate Lending Fund

Monroe Capital Enhanced Corporate Lending Fund Capital Raise

Monroe Capital Enhanced Corporate Lending Fund completed private offerings of Class S and Class D common shares along with promissory notes to 110 accredited investors, raising approximately $152,000 in net proceeds. In connection with these offerings, the Fund reached its minimum shareholder threshold and terminated its existing escrow agreement with U.S. Bank and other parties as the escrow arrangement was no longer required.

Counterparty
110 separate investors
9:58 AM ET 10-Q
Financial Results Golden Growers Cooperative GGROU

Golden Growers Cooperative Q3 2026 Results: Net Income $1.31M, Down 6.9% YoY

Golden Growers Cooperative reported net income of $4.2 million for the nine months ended September 30, 2026, a slight decrease from $4.5 million in the prior year. The Cooperative's financial position remains influenced by its 50% interest in ProGold LLC, which contributed $4.67 million in net income during the period, while members' equity decreased to $13.6 million following $10.7 million in distributions.

Key figure
Net income $1.31M · -6.9% YoY
9:56 AM ET 10-Q
Financial Results Trinseo PLC TSEOQ

Trinseo Q3 2026 Results: Net Loss of $49.1M, Loss Narrows

Trinseo PLC filed for Chapter 11 bankruptcy on May 26, 2026, to facilitate a comprehensive capital restructuring. As of September 30, 2026, the company reported total assets of $2,456.6 million and a significant increase in short-term borrowings and current debt to $589.6 million compared to $212.9 million at year-end 2025.

Key figure
Net loss $49.1M
9:49 AM ET 8-K
Clinical Trial Data Oncolytics Biotech Inc ONCY

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced translational data from a Phase 1b/2 trial evaluating pelareorep in patients with relapsed/refractory multiple myeloma. Single-cell sequencing demonstrated that pelareorep engaged the immune system, remodeled the tumor microenvironment, and increased populations of CD8 effector memory T cells. The data, which showed greater T cell expansion in clinical responders, will be presented at the 68th ASH Annual Meeting.

9:41 AM ET 10-Q
Financial Results Choiceone Financial Services Inc COFS

Choiceone Financial Services Q3 2026 Results: Net Income $14.5M, Down 0.9% YoY

ChoiceOne Financial Services reported net income of $40.7 million for the first nine months of 2026, a significant increase from $14.3 million in the same period of 2025, which was impacted by $17.4 million in merger-related expenses. Total assets grew slightly to $4.46 billion, while the company experienced a notable increase in accumulated other comprehensive loss due to unrealized losses on available-for-sale securities.

Key figure
Net income $14.5M · -0.9% YoY
9:35 AM ET Form 4
Insider Selling Cullen/Frost Bankers, Inc. CFR

Cullen/Frost Bankers President of CFR Paul Bracher Sells $459K of Stock

Paul Bracher, President of CFR, sold 2,900 shares of Cullen/Frost Bankers, Inc. at $158.24 a share, worth $459K in total on Nov 5, 2026. Shares held after the trade: 108,736 (-2.6%).

Value
$459K
Shares
2,900
Price
$158.24
Role
President of CFR
Holding change
-2.6%
Trade date
Nov 5, 2026
9:31 AM ET 8-K
Investor Presentation Crexendo, Inc. CXDO

Crexendo Investor Presentation

Crexendo, Inc. has posted an updated investor presentation to its website and filed it as an exhibit to this 8-K. The presentation, dated November 2026, provides a strategic and operational overview of the company for investors and analysts.

9:23 AM ET 8-K
Capacity Expansion Exascale Labs Holdings Inc. XLAB

Exascale Labs Holdings Capacity Expansion: $9.04M Investment

Exascale Labs Holdings Inc. entered into a firm order to purchase 16 Intel BHS 10U GPU servers equipped with NVIDIA HGX B300 GPUs from Compal Electronics for $9.04 million. The purchase is part of a larger framework agreement allowing the company to acquire up to 128 servers for a total potential value of $72.32 million through March 2027. This acquisition represents a material investment in the company's physical high-performance computing infrastructure.

Value
$9.04M
Counterparty
Compal Electronics, Inc.
Term
through March 31, 2027
9:23 AM ET 8-K
Clinical Trial Data Werewolf Therapeutics, Inc. HOWL

Werewolf Therapeutics Clinical Trial Data

Werewolf Therapeutics announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330 for the treatment of solid tumors at the SITC 2026 Annual Meeting. WTX-124 demonstrated durable antitumor activity, including a complete response in a patient with cutaneous squamous cell carcinoma, and the company aligned with the FDA on a recommended Phase 2 dose of 18 mg. WTX-330 was reported as well-tolerated with evidence of monotherapy clinical activity in advanced, treatment-refractory disease.

9:21 AM ET 8-K
Clinical Trial Data Nkarta, Inc. NKTX

Nkarta Clinical Trial Data

Nkarta announced positive initial clinical data from its Ntrust program evaluating NKX019, an allogeneic CAR NK cell therapy, for myositis and systemic sclerosis. In the 4 billion cells per dose cohort, 83% of myositis patients achieved moderate or major responses, while 86% of systemic sclerosis patients achieved an rCRISS-25 response or greater. The therapy demonstrated a favorable safety profile with no cases of CRS, ICANS, or GvHD across 40 treated patients.

9:17 AM ET 8-K
Business Update TMC the metals Co Inc. TMC

TMC the metals Co Business Update

TMC's subsidiary received notification from NOAA regarding the expected timeline for a certification determination on its deep seabed exploration and commercial recovery application. NOAA expects to provide its final determination by mid-December 2026, which serves as an intermediate step in the regulatory review process under the Deep Seabed Hard Mineral Resources Act.

Counterparty
National Oceanic and Atmospheric Administration
9:16 AM ET 8-K
M&A Deal Surgery Partners, Inc. SGRY

Surgery Partners Signs $6B M&A Deal with HealthSpan Partners

Surgery Partners entered into an amendment to its merger agreement with HealthSpan Partners (an affiliate of Bon Secours Mercy Health), increasing the cash consideration to $25.00 per share. The deal includes a 'ticking fee' of up to $1.61 per share if closing is delayed past March 1, 2027, bringing the total enterprise value to approximately $6.0 billion. The amendment follows an unsolicited $28.00 per share competing proposal from a third party, which the board determined was less favorable due to regulatory and closing certainty provided by HealthSpan.

Value
$6B
Counterparty
HealthSpan Partners

“We are pleased to have reached this outcome, which reflects the rigorous focus of our Board of Directors and Special Committee throughout this process on delivering the best possible result for Surgery Partners and our stockholders. This transaction provides exceptional value for our stockholders, along with regulatory certainty and a closing expected in the near term.”

Eric Evans, Chief Executive Officer of Surgery Partners
9:09 AM ET 8-K/A
M&A Deal Fox Corp FOXA

Fox M&A Deal with Roku, Inc.

Fox Corporation completed the acquisition of Roku, Inc. on November 6, 2026, for a combination of cash and FOX Class A Common Stock. This filing provides the required historical financial statements of Roku and pro forma financial information following the consummation of the transaction. Fox expects to realize synergies and operational efficiencies from the integration of Roku's streaming platform into its media business.

Counterparty
Roku, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.